Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516073 · ClinicalTrials.gov registry record · Phase 2
12-Week Study in Adult Subjects With Asthma
A Phase 2 study of Asthma, sponsored by Dey.
- Completed
- Registry status
- Phase 2
- Development phase
- 629
- Enrollment target
- 1
- Study location
NCT01516073: Completed Phase 2 study of Asthma, sponsored by Dey.
NCT01516073 is a Phase 2 study of Asthma that has completed, run by Dey. The registered enrollment target is 629 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01516073, a Phase 2 study of Asthma, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 629 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a multi-center, randomized, placebo-controlled parallel-group study to evaluate nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled and uncontrolled asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-blind treatment.
Conditions Studied
Interventions
- DRUG Fluticasone Propionate
Study Locations (1)
South Carolina
- Greenville Pharmaceutical research, Inc. - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT01516073 record still lists
NCT01516073 is an interventional study that assigns participants to a tested intervention. The registered 629 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Fluticasone Propionate is the first listed.
NCT01516073 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT01516073 about?
NCT01516073 is a clinical study titled "12-Week Study in Adult Subjects With Asthma". This will be a multi-center, randomized, placebo-controlled parallel-group study to evaluate nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled and uncontrolled asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-bli...
What is the current status of trial NCT01516073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 629 participants. The study started on 2012-03. Estimated completion is 2013-11.
What conditions does trial NCT01516073 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01516073?
The interventions under investigation include: Fluticasone Propionate (DRUG).
Who is sponsoring clinical trial NCT01516073?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01516073 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01516073's enrollment target sits among peer trials
629 62nd of 374 higher than 313 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia